Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)

Next Previous
Trial Profile

Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifinatamab deruxtecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms IDeate-Pantumor01
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 13 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
  • 07 Nov 2024 According to Florida Cancer Specialists & Research Institute media release, results from this study being presented this week at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston.
  • 11 Jan 2024 Planned number of patients changed from 205 to 250.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top